|
| 36321991 | Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 36321991 | Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 37597578 | Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. | Ann Oncol | 2023 |
| 37626587 | Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models. | Biomedicines | 2023 |
| 36579470 | Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. | Cancer | 2023 |
| 37268193 | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial. | Pract Radiat Oncol | 2023 |
| 36753688 | Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study. | JCO Precis Oncol | 2023 |
| 36750617 | Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. | Commun Med (Lond) | 2023 |
| 36630671 | An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials. | JCO Oncol Pract | 2023 |
| 36735117 | A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. | Breast Cancer Res Treat | 2023 |
| 37497337 | Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. | Cancer Res Commun | 2023 |
| 37597578 | Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. | Ann Oncol | 2023 |
| 37626587 | Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models. | Biomedicines | 2023 |
| 37497337 | Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit. | Cancer Res Commun | 2023 |
| 37268193 | Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial. | Pract Radiat Oncol | 2023 |
| 36753688 | Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study. | JCO Precis Oncol | 2023 |
| 36750617 | Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. | Commun Med (Lond) | 2023 |
| 36579470 | Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. | Cancer | 2023 |
| 36735117 | A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. | Breast Cancer Res Treat | 2023 |
| 36630671 | An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials. | JCO Oncol Pract | 2023 |
| 34615724 | <sup>18</sup>F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition. | Clin Cancer Res | 2022 |
| 35588469 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. | J Clin Oncol | 2022 |
| 35579777 | A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. | Sci China Life Sci | 2022 |
| 36008408 | Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling. | Nat Commun | 2022 |
| 35939768 | Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. | JCO Precis Oncol | 2022 |
| 35795040 | The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. | Front Oncol | 2022 |
| 35852875 | An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases. | JCI Insight | 2022 |
| 36751656 | Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2022 |
| 35294185 | Poly(<i>N</i>-vinylpyrrolidone)-<i>block</i>-Poly(dimethylsiloxane)-<i>block</i>-Poly(<i>N</i>-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast Cancers. | ACS Appl Bio Mater | 2022 |
| 34615724 | <sup>18</sup>F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition. | Clin Cancer Res | 2022 |
| 35205763 | Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer. | Cancers (Basel) | 2022 |
| 35579777 | A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. | Sci China Life Sci | 2022 |
| 35795040 | The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. | Front Oncol | 2022 |
| 35852875 | An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases. | JCI Insight | 2022 |
| 35588469 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. | J Clin Oncol | 2022 |
| 36751656 | Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2022 |
| 35939768 | Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. | JCO Precis Oncol | 2022 |
| 36008408 | Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling. | Nat Commun | 2022 |
| 35205763 | Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer. | Cancers (Basel) | 2022 |
| 35294185 | Poly(<i>N</i>-vinylpyrrolidone)-<i>block</i>-Poly(dimethylsiloxane)-<i>block</i>-Poly(<i>N</i>-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast Cancers. | ACS Appl Bio Mater | 2022 |
| 32570285 | Role of orbitofrontal cortex in incubation of oxycodone craving in male rats. | Addict Biol | 2021 |
| 32350670 | Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer. | Support Care Cancer | 2021 |
| 33577866 | A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. | Radiother Oncol | 2021 |
| 34108261 | Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. | Mol Cancer Ther | 2021 |
| 33674745 | PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1. | Oncogene | 2021 |
| 33663560 | An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. | Breast Cancer Res | 2021 |
| 34298684 | The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. | Cancers (Basel) | 2021 |
| 32570285 | Role of orbitofrontal cortex in incubation of oxycodone craving in male rats. | Addict Biol | 2021 |
| 34631532 | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. | Front Oncol | 2021 |
| 34452008 | Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers. | Vaccines (Basel) | 2021 |